NASDAQ:BIB ProShares Ultra Nasdaq Biotechnology (BIB) Price, Holdings, & News $106.89 -0.70 (-0.65%) Closing price 03:52 PM EasternExtended Trading$106.92 +0.02 (+0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsSEC FilingsTrendsBuy This Stock About ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIB alerts:Sign Up Key Stats Today's Range$103.97▼$106.8750-Day Range$78.07▼$109.7852-Week Range$54.56▼$110.25Volume6,223 shsAverage Volume10,994 shsMarket Capitalization$86.58 millionAssets Under Management$88.07 millionDividend Yield0.30%Net Expense Ratio0.95%Aggregate RatingModerate Buy ETF Overview ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund. Read More ProShares Ultra Nasdaq Biotechnology ExpensesTypeBIBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.55%0.57%0.54%0.53%Other Expenses0.44%0.52%0.53%0.39%0.54%Total Expense1.19%0.76%0.75%0.69%0.73%Fee Waiver-0.24%-0.85%-0.67%-0.41%-0.68%Net Expense0.95%0.58%0.63%0.61%0.60% Receive BIB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares Ultra Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIB ETF News HeadlinesProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Above 50 Day Moving Average - Here's What HappenedAugust 12 at 3:41 AM | americanbankingnews.comProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Above Fifty Day Moving Average - Here's What HappenedAugust 4, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.August 14 at 1:00 AM | Stansberry Research (Ad)ProShares Ultra Nasdaq Biotechnology declares quarterly distribution of $0.0071March 26, 2026 | msn.comBIB: A Tactical 2 X Leveraged Biotech ETFOctober 23, 2025 | seekingalpha.comUltraShort Nasdaq Biotechnology declares quarterly distribution of $0.1542September 25, 2025 | msn.comSee More Headlines BIB ETF - Frequently Asked Questions How have BIB shares performed this year? ProShares Ultra Nasdaq Biotechnology's stock was trading at $79.78 on January 1st, 2026. Since then, BIB stock has increased by 34.0% and is now trading at $106.8910. How do I buy shares of ProShares Ultra Nasdaq Biotechnology? Shares of BIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares Ultra Nasdaq Biotechnology investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Salesforce (CRM). Fund Details IssuerProShares Fund NameProShares Ultra Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:BIB Inception Date4/7/2010 Fund ManagerMichael Neches, Tarak Dave Webwww.proshares.com Phone+1-240-4976400Fund Focus Asset ClassEquity BenchmarkNasdaq Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings268 Fund Statistics Assets Under Management$88.07 million Average Daily Volume$8.15 thousand Discount/Premium0.19% Leveraged2.00 Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors, LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume2 Put Options2 Call Options0 Miscellaneous Outstanding Shares810,000Beta1.20 Creation Unit50,000 Creation Fee$250.00 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report Top 10 BIB HoldingsNASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAHolding Weight: 34.92%NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAHolding Weight: 33.01%NASDAQ BIO INDEX SWAP BNP PARIBASHolding Weight: 32.99%NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONALHolding Weight: 20.76%NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEHolding Weight: 19.77%NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGHolding Weight: 4.98%Amgen (NASDAQ:AMGN)Holding Weight: 4.65%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 4.23%Gilead Sciences (NASDAQ:GILD)Holding Weight: 3.78%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 2.94%Full Holdings DetailsBIB Sector ExposureBIB Industry Exposure This page (NASDAQ:BIB) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredOne wafer-scale chip does in minutes what AI takes daysNVIDIA has dominated the AI computing race, but history shows even titans can be dethroned, just ask IBM. T...Eagle Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
